HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases

Area of Science:

• Epigenetics
• Molecular Biology
• Pharmacology

Background:

• Histone deacetylases (HDACs) regulate gene expression via chromatin remodeling.
• HDAC inhibition is a therapeutic strategy for epigenetic alterations.
• Preclinical studies show HDAC inhibitors possess anticancer properties.

Purpose of the Study:

• To review HDAC inhibitors, their mechanisms of action, and therapeutic potential.
• To emphasize the role of HDAC inhibitors in treating Chronic Obstructive Pulmonary Disease and lung cancer.
• To discuss nanocarrier-mediated delivery and novel targeting strategies for HDAC inhibitors.

Main Methods:

• Literature review of preclinical and clinical research on HDAC inhibitors.
• Analysis of HDAC inhibitor mechanisms in epigenetic regulation.
• Exploration of therapeutic applications in oncology and respiratory diseases.

Main Results:

• HDAC inhibitors demonstrate significant anticancer activity.
• The effects of HDAC inhibitors are complex and multifaceted.
• Emerging evidence suggests potential in treating Chronic Obstructive Pulmonary Disease.

Conclusions:

• HDAC inhibitors represent a promising therapeutic class.
• Targeting HDACs offers a viable strategy for lung cancer and COPD.
• Advanced delivery systems and targeting methods are crucial for optimizing HDAC inhibitor therapy.